All In Biotech

Drug Trial Radar · NCT05571345

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone Immediate-Release Tablets and Placebo in Non-Dependent Recreational Opioid Users

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Oct 5, 2022

Primary completion

Dec 23, 2022

Study completion Dec 28, 2022

Sponsor

Lead sponsor
Ensysce BiosciencesIndustry
Sponsor type
Industry
Collaborators
Dr. Vince Clinical Research
First posted
Oct 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a randomized, double-blind, placebo- and active-controlled, 5-way crossover study to evaluate the abuse potential, safety and pharmacokinetics of orally administered PF614 relative to oxycodone IR (immediate-release) tablets and placebo.

Conditions

  • Recreational Drug Use

Interventions

  • PF614Drug

    PF614 capsules (50 mg or 100 mg)

  • Oxycodone Hydrochloride 40 mgDrug

    Oral 20 mg tablets (two each)

  • PlaceboDrug

    Placebo to match PF614 capsules will be provided by the sponsor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS)Time frame: Up to 24 hour post-dose (up to Day 2)
  2. Take Drug Again VAS (Emax)Time frame: 12 hours post-dose
  3. Take Drug Again VAS (Emax)Time frame: 24 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Vince Clinical Research

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.